News AstraZeneca files Imfinzi for groundbreaking lung cancer use AZ also unveils promising results from early-stage lung cancer combination
Partner Content Partner Content ProQR Therapeutics: RNA Therapeutics for Patients with Cysti... RNA Therapeutics
News BMS scores an early victory in the new cancer biomarker batt... Bristol-Myers Squibb is hoping to drive forward its Opdivo cancer immunotherapy franchise by finding a better biomarker than PD-L1 - and has just produced encouraging results in a trial loo
News EU regulators back J&J's Zytiga in early prostate cancer use New use could give J&J drug edge over Pfizer's rival
News Cancer drug could cost NHS £4.7m per year of patient life, s... Roche's Erivedge is latest cancer drug to fall foul of NICE number-crunching.
News FDA rejects Mylan and Biocon biosimilar, citing manufacturin... Neulasta biosimilar hits trouble with regulators because of manufacturing issues
Patients Making direct-to-patient work, with Matt Wadyka Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
